GlassScriptPhysician profile
William Joseph Wiseman
NPI 1356323323
$3,461.32
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,464 · 2020: $938 · 2021: $59.98.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $736.26 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $657.61 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $656.07 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $355.89 | 2019-2020 | |
| Lundbeck LLC | $328.59 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $182.56 | 2019 | |
| Shire North American Group INC | $93.86 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $83.64 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $76.38 | 2019-2020 | |
| Tris Pharma INC | $76.21 | 2019-2021 | |
| Neos Therapeutics, LP | $46.17 | 2019-2020 | |
| Abbvie INC. | $41.54 | 2021 | |
| Ironshore Pharmaceuticals INC. | $40.54 | 2019-2020 | |
| Bausch Health US, LLC | $27.95 | 2020 | |
| Avanir Pharmaceuticals, INC. | $23.75 | 2019-2020 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $21.19 | 2019 | |
| Currax Pharmaceuticals LLC | $13.11 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Wiseman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.